Tvardi Announces Phase 1 Results for TTI-109 and Upcoming HCC Data
Tvardi Therapeutics reported positive Phase 1 data for TTI-109 in ulcerative colitis and expects top-line results for TTI-101 in hepatocellular carcinoma in early 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed